Prognostic value of androgen receptor expression in different molecular types of breast cancer in women

Author:

Elbalka Saleh S.1,Metwally Islam H.1,Hassan Amany2,Eladl Ahmed E.2,Shoman Ahmed M.3,Jawad Mohamed3,Shahda Eman3,Abdelkhalek Mohamed1

Affiliation:

1. , Oncology Center Mansoura University (OCMU), , Egypt

2. , , Mansoura University, , Egypt

3. , Mansoura University, , Egypt

Abstract

BACKGROUND: Breast cancer is a common women's disease. Usually, oestrogen is blamed in the aetiology and correlated with the prognosis; however, androgens are recently raising concern about its role in the breast cancer treatment and prognosis. METHODS: In this study we retrieved archival paraffin blocks of breast cancer patients and stained it for androgen. Thereafter, we compared clinico-epidemiologic parameters, histopathology, neoadjuvant response and recurrence rate and pattern among patients with and without androgen receptor (AR) expression. RESULTS: In total, 119 patients fulfilled enrolment criteria; AR expression were present in 77.3% of the patients. AR expression was associated with less grade III (6.8% versus 36.4%), and less triple negative (6.2% versus 25%), but similar overall recurrence rate (25% versus 22.2%). However, distant recurrence was significantly higher in androgen positive patients (91.3% versus 33.3% of all recurrences). CONCLUSION: Androgen expression appears to be common among breast cancer, but with no clear implication in tumour aggressiveness or effect on the rate of recurrence. However, being commonly associated with distant spread may have an impact on survival of the patients.

Publisher

IOS Press

Subject

Cancer Research,Oncology,General Medicine

Reference17 articles.

1. Targeting the androgen receptor in breast cancer;Chia;Current Oncology Reports,2015

2. Kraby MR, The prognostic value of androgen receptors in breast cancer subtypes,, 172(2): 283–296, 2018. Au: Please provide journal title for ref. [2].

3. Testosterone propionate therapy in breast cancer;Goldenberg;JAMA,1964

4. Therapeutic activity of testosterone in metastatic breast cancer;Boni;Anticancer Res,2014

5. Anti-androgen therapy in triple-negative breast cancer;Barton;Therapeutic Advances in Medical Oncology,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3